An interventional study of Myocardium biopsy in Aortic Valve Stenosis, sponsored by University Hospital, Strasbourg, France. Withdrawn at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Basic science
The aim of the study is to evaluate the expression of Sodium Glucose Co-transporter 2 (SGLT2) in myocardium from patients with aortic stenosis. 2 groups of patients will be defined: Group A with diastolic heart failure and Group B without heart failure. The expression of SGLT2 will be measured on small myocardium specimens harvested during aortic valve replacement operation. This study should allow us to better understand the effect of glifozines in human heart failure.
985 studies on the registry are indexed under Aortic Valve Stenosis; 282 are open to participants now.
Browse Aortic Valve Stenosis studies →University Hospital, Strasbourg, France is the lead sponsor of 968 studies on the registry; 344 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Biological: Myocardium biopsy
Biological: Myocardium biopsy
The expression of SGLT2 on small myocardium specimens harvested during aortic valve replacement operation in patients with aortic stenosis
To study the expression levels of SGLT2 in the myocardium of patients with surgical aortic stenosis
Measure of SGLT2 expression level by RT-PCR and
Time frame: Day 0
To study the SGLT2 tissue localization in the myocardium of patients with surgical aortic stenosis
SGLT2 expression level by immunofluorescence labeling
Time frame: Day 0
Comparison of SGLT2 expression levels between heart failure and non-heart failure patients.
SGLT2 expression levels between the 2 groups of patients
Time frame: Day 0
Assess oxidative stress
Pro-oxidant response (fluorescence level of the redox-sensitive fluorescent probe DHE)
Time frame: Day 0
Evaluate the pro-inflammatory response by analysing the expression level of tissue activation molecules VCAM-1, ICAM-1, MCP-1
Pro-inflammatory response: (VCAM-1, ICAM-1, MCP-1). Expression level of tissue activation molecules VCAM-1, ICAM-1, MCP-1 by RT-PCR, Western blot analysis and immunofluorescence labeling
Time frame: Day 0
Evaluate the pro-fibrotic response
Pro-fibrotic response: TGF beta, Ang II, AT1R, ACE, collagen; MMP-2, MMP-9. Expression level of molecules involved in tissue remodeling TGF beta, Ang II, AT1R, ACE, collagen, MMP-2, MMP-9 by RT-PCR, Western blot analysis and immunofluorescence labeling
Time frame: Day 0
Evaluate the pro-senescent response
Pro-senescent response: SA-beta-galactosidase activity, p53, p21, P16. Determination of senescence-associated beta-galactosidase activity on cardiac muscle cryosections, and expression level of senescence mediators p53, p21, p16 by RT-PCR, Western blot analysis and immunofluorescence labeling
Time frame: Day 0
Evaluate the pro-thrombotic response
Pro-thrombotic response: tissue factor. Expression level of coagulation cascade activator, tissue factor by RT-PCR, Western blot analysis and immunofluorescence labeling
Time frame: Day 0
Evaluate endothelial dysfunction
Endothelial response: eNOS, NO, nitrotyrosine. Expression level of eNOS and nitrotyrosine by RT-PCR, Western blot analysis and immunofluorescence labeling and NO formation using the NO-sensitive fluorescent probe, DAF-FM on heart muscle cryosections
Time frame: Day 0
This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France